PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31591140-1	2020	BACKGROUND: Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC).	tipiracil	29-38	triosephosphate isomerase 1	Homo sapiens	46-49	
31591140-12	2020	IMPLICATIONS FOR PRACTICE: Trifluridine plus tipiracil (FTD + TPI) and regorafenib (REG) prolong survival in refractory metastatic colorectal cancer (mCRC) but have different tolerability profiles.	tipiracil	45-54	triosephosphate isomerase 1	Homo sapiens	62-65